

Appl. No. 10/608,886
Amendment and Response to Restriction Requirement
Page 9 of 16

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A composition for inhibiting ~~protein~~proteinase activated receptor activity comprising a protein, peptide, biomolecule or active fragment thereof.
2. (Currently Amended) The composition of Claim 1, wherein the ~~protein~~proteinase activated receptor comprises PAR-1, PAR-2, PAR-3 or PAR-4.
3. (Currently Amended) The composition of Claim 1, wherein the protein, peptide, or biomolecule comprises LIGK (SEQ ID NO:1), LIGKV (SEQ ID NO:2), KGIL (SEQ ID NO:3), KGI (SEQ ID NO:4), AGI (SEQ ID NO:5), IGA (SEQ ID NO:6), KGA (SEQ ID NO:7), KGA (SEQ ID NO:8), KAI (SEQ ID NO:9), IAK (SEQ ID NO:10), RGI (~~SEQ ID NO:11~~)(SEQ ID NO:11), IGR (SEQ ID NO:12), Dab-GI (~~SEQ ID NO:13~~)(SEQ ID NO:13), Dap-GI (SEQ ID NO:14), IG-Dab (~~SEQ ID NO:15~~)(SEQ ID NO:15), IG-Dap (SEQ ID NO:16), LIG-Dab (SEQ ID NO:17), Dab-GIL (SEQ ID NO:18), LIG-Dap (SEQ ID NO:19), Dap-GIL (SEQ ID NO:20), LIG-Om (SEQ ID NO:21), Om-GIL (~~SEQ ID: 22~~)(SEQ ID NO:22), Om-GI (SEQ ID NO:23), IG-Om (SEQ ID NO:24), ENMD 545, ENMD 547 ~~and~~ or active fragments thereof.
4. (Currently Amended) The composition of Claim 3, wherein the ~~protein~~proteinase activated receptor comprises PAR-2.
5. (Currently Amended) The composition of Claim 1, wherein the ~~protein~~proteinase activated receptor comprises PAR-2 and ~~wherein the~~ wherein the protein, peptide, or biomolecule comprises LIGK (SEQ ID NO:1).

Appl. No. 10/608,886
Amendment and Response to Restriction Requirement
Page 10 of 16

6. (Currently Amended) The composition of Claim 1, wherein the ~~protein~~ proteinase activated receptor comprises PAR-2 and ~~wherein the~~ wherein the protein, peptide, or biomolecule comprises ENMD 547.

7. (Original) The composition of Claim 1, further comprising a pharmaceutically acceptable carrier.

8. (Withdrawn-Currently Amended) A method for inhibiting ~~protein-proteinase~~ activated receptor activity in a subject comprising administering to said subject the composition of Claim 1 comprising a protein, peptide, biomolecule or active fragment thereof.

9. (Withdrawn-Currently Amended) The method of Claim 8, wherein the ~~protein-proteinase~~ activated receptor comprises PAR-1, PAR-2, PAR-3 or PAR-4.

10. (Withdrawn-Currently Amended) The method of Claim 8, wherein the protein, peptide, or biomolecule comprises LIGK (SEQ ID NO:1), LIGKV (SEQ ID NO:2), KGIL (SEQ ID NO:3), KGI (SEQ ID NO:4), AGI (SEQ ID NO:5), IGA (SEQ ID NO:6), KGA (SEQ ID NO:7), KGA (SEQ ID NO:8), KAI (SEQ ID NO:9), IAK (SEQ ID NO:10), RGI (~~SEQ ID NO:11~~)(SEQ ID NO:11), IGR (SEQ ID NO:12), Dab-GI (~~SEQ ID NO:13~~)(SEQ ID NO:13), Dap-GI (SEQ ID NO:14), IG-Dab (~~SEQ ID NO:15~~)(SEQ ID NO:15), IG-Dap (SEQ ID NO:16), LIG-Dab (SEQ ID NO:17), Dab-GIL (SEQ ID NO:18), LIG-Dap (SEQ ID NO:19), Dap-GIL (SEQ ID NO:20), LIG-Om (SEQ ID NO:21), Om-GIL (~~SEQ ID NO:22~~)(SEQ ID NO:22), Om-GI (SEQ ID NO:23), IG-Om (SEQ ID NO:24), ENMD 545, ENMD 547 ~~and or~~ active fragments thereof.

11. (Withdrawn-Currently Amended) The method of Claim 8, wherein the ~~protein-proteinase~~ activated receptor comprises PAR-2.

Appl. No. 10/608,886
Amendment and Response to Restriction Requirement
Page 11 of 16

12. (Withdrawn-Currently Amended) The method of Claim 8, wherein the ~~protein-proteinase~~ activated receptor comprises PAR-2 and ~~wherein the~~ wherein the protein, peptide, or biomolecule comprises LIGK (SEQ ID NO:1).

13. (Withdrawn-Currently Amended) The method of Claim 8, wherein the ~~protein-proteinase~~ activated receptor comprises PAR-2 and ~~wherein the~~ wherein the protein, peptide, or biomolecule comprises ENMD 547.

14. (Withdrawn) The method of Claim 8, further comprising a pharmaceutically acceptable carrier.

15. (Withdrawn-Currently Amended) A method for treating a disorder associated with abnormal ~~protein-proteinase~~ activated receptor activity comprising administering to a subject in need of such treatment, ~~a~~ the composition of Claim 1 comprising a protein, peptide, biomolecule or active fragment thereof capable of inhibiting ~~protein~~ proteinase activated receptor activity.

16. (Withdrawn-Currently Amended) The method of Claim 15, wherein the protein, peptide, or biomolecule comprises LIGK (SEQ ID NO:1), LIGKV (SEQ ID NO:2), KGIL (SEQ ID NO:3), KGI (SEQ ID NO:4), AGI (SEQ ID NO:5), IGA (SEQ ID NO:6), KGA (SEQ ID NO:7), KGA (SEQ ID NO:8), KAI (SEQ ID NO:9), IAK (SEQ ID NO:10), RGI (~~SEQ ID NO:11~~)(SEQ ID NO:11), IGR (SEQ ID NO:12), Dab-GI (~~SEQ ID NO:13~~)(SEQ ID NO:13), Dap-GI (SEQ ID NO:14), IG-Dab (~~SEQ ID NO:15~~)(SEQ ID NO:15), IG-Dap (SEQ ID NO:16), LIG-Dab (SEQ ID NO:17), Dab-GIL (SEQ ID NO:18), LIG-Dap (SEQ ID NO:19), Dap-GIL (SEQ ID NO:20), LIG-Om (SEQ ID NO:21), Om-GIL (~~SEQ ID NO:22~~)(SEQ ID NO:22), Om-GI (SEQ ID NO:23), IG-Om (SEQ ID NO:24), ENMD 545, ENMD 547 ~~and~~ or active fragments thereof.

Appl. No. 10/608,886
Amendment and Response to Restriction Requirement
Page 12 of 16

17. (Withdrawn-Currently Amended) The method of Claim 15, wherein the disorder comprises an angiogenic disease, ~~undesireable~~ undesirable neovascularization, inflammation, tumor growth, sepsis, neurogenic inflammatory pain, asthma, post operative ileus ~~and~~ or cancer.

18. (Withdrawn) The method of Claim 17, wherein the disorder comprises inflammation and wherein the protein, peptide, or biomolecule comprises LIGK (SEQ ID NO:1).

19. (Withdrawn) The method of Claim 17, wherein the disorder comprises inflammation and wherein the protein, peptide, or biomolecule comprises ENMD 547.

20. (Withdrawn-Currently Amended) The method of Claim 15, further comprising a pharmaceutically acceptable carrier.